NCT00833729View on ClinicalTrials.gov

The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Plaque Psoriasis
Interventions
DRUG

etanercept

50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.

Trial Locations (1)

L8N 1V6

Dermatrials Research, Hamilton

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Dermatrials Research

OTHER